- 1 A comparative study of multidrug resistant bacteria (MDRB) isolated from various patients in
- 2 different wards of a hospital during post Covid-19
- 4 Abhishek Ojha^{1□}, Dwight Figueiredo¹, Shabnum Khan¹
- ¹ Symbiosis Institute of Health Sciences, Symbiosis International (Deemed University),
- 6 Lavale (Hill Base), Pune 412115, Maharashtra, India.
- ^{*} Corresponding author; Abhishek Ojha; Email: ab.ojha@gmail.com
- 8 Dwight Figueiredo; Email: drdwight@sihspune.org
- 9 Shabnum Khan; Email: 42khanshabnum@gmail.com

Abstract

3

10

11

- 12 Antibacterial resistance is an alarming global concern and a public health challenge of the
- twenty-first century for which effective systems are required to track and treat ABR. We
- 14 performed microbiological and antibiotic susceptibility testing on the samples to detect and
- 15 characterize Multidrug-Resistant Bacteria (MDRB) isolated from patients segregating MDRB
- 16 characteristics (types, prevalence and distribution of MDRB) based on time (i.e., during
- 17 versus post covid-19) and location (i.e., different wards of a tertiary care hospital). We
- observed an increase of MDRB in 2022 as compared to 2021 and 2023. These MDRB had a
- 19 Shannon and Simpson index values of 1.138 to 1.508 and 0.643 to 0.775, respectively and an
- 20 observed evenness values of 0.780 to 1.042, which revealed the microbial diversity recovered
- 21 from the patient samples. In keeping with previous MDR studies, Klebsiella, E. coli,
- 22 Citrobacter, Acinetobacter and Pseudomonas were identified from the patient samples.
- 23 Moreover, compared to previous reports, the percentage of MDR-bacteria, i.e., *Klebsiella* (40

%), *E. coli* (28 %), and *Citrobacter* (19 %), populations were higher in this study. We observed that Gamma-proteobacteria were predominant across all the recovered samples, and that *Acinetobacter* and *Klebsiella* isolated from the samples were 100 % resistant to twenty and eleven antibiotics, respectively. Furthermore, the fatality rate was low compared with the available reports suggesting possibilities for effective recovery if given rapid and tailored treatment. Given the challenges faced by MDRB strains more surveillance and tracking is needed to ensure effective and specifically targeted treatment strategies.

- **Keywords**: Multi-drug resistant, Microbes, Antimicrobial susceptibility testing, comorbid,
- 32 Covid-19, Healthcare.

1. Introduction

Over the previous decades, it has been observed that antibiotic resistance is increasing to precariously high levels all over the world as new mechanisms of resistance are looming and spreading worldwide (Alós et al., 2015; Hernando-Amado et al., 2019). Widespread, non-specific, and uninterrupted use of antibacterial antibiotics in treating bacterial infections has been well documented in fuelling resistance among the distinct elements of bacterial populations (Klein et al., 2018; Carvalho et al., 2022). Due to the continuous need of antibacterial substances active against resistant gram-negative microflora, gram-positive multi drug resistant (MDR) pathogens have been overwhelmed by gram-negative bacterial infections (Jones, 2001). Among gram-negative microflora, the commonest MDR microbes identified in severe patients are *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia*, *Acinetobacter* sp., *and Enterobacteriaceae*. *Staphylococcus aureus* (methicillin-resistant) and *Enterococci* sp. (vancomycin-resistant) are the most common gram-positive isolated, although their occurrence is falling (Jones, 2001; Boucher et al., 2009). Hospital-acquired infections (HAIs) have been known for over a century as a critical clinical issue affecting

healthcare quality, and they are the primary source of unfavourable healthcare outcomes (Aly et al., 2008; Memish and El-Saed, 2009; Nannini et al., 2009). The development of MDR microbes (MDRM) in the patient has become a public health issue, emerging as a new concern in many parts of the health system or hospitals (Jindal et al., 2015; Dogru et al., 2010; Teng et al., 2009; Aly et al., 2008). There is extensive use of antibiotics as a drug in critical care units, which establishes a selection burden and stimulates the development of MDRM (Teng et al., 2009; Aly et al., 2008). Further, an intensive care unit (ICU) patient is known to have a high risk of infection due to their underlying health conditions, exposure to various invasive devices, and weakened immunity (Dettenkofer et al., 2001; Ylipalosaari et al., 2006). The HAI rate in general wards is lower than that of ICU-HAI (Weinstein, 1998). The ICU-HAI has been associated with higher costs, morbidity, and mortality (Iskandar et al., 2021; Neidell et al., 2012; Montassier et al., 2013; Gastmeier et al., 2005). The objective of this research was to investigate HAI in various (ICUs, neonatal ICU (NICU), outpatient departments (OPD), male wards, female wards, pediatric wards, and medicine wards) departments to reveal the MDR microbial community, the anti-microbial resistance descriptions, including their effect on MDRM-related mortality and comorbidity.

2. Materials and methods

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

66

67

68

69

70

71

65 *2.1. Site of study and patients*

The study was performed as single-centre retrospective research at a 900-bed hospital (the Symbiosis University Hospital and Research Centre, SUHRC, Pune, Maharashtra, India), providing quality healthcare to the Pune's surrounding rural and upcoming urban areas. High patient numbers ensure extensive contact with the local community flows daily due to subsidized healthcare facilities and treatment strategies provided. The hospital provides for both inpatient and outpatient patient treatment services. The hospital possesses operation

73

74

77

84

86

88

89

91

94

95

theatres, ICUs, NICUs, Wards, OPDs. During Covid-19 (Coronavirus disease-2019), the hospital ran with specialized wards assigned to Covid-19-positive patients. The standard infection control measures (PPE, personal protective equipment) and sterilization protocols 75 (https://www.england.nhs.uk/national-infection-prevention-and-control-manual-nipcm-for-76 england/chapter-1-standard-infection-control-precautions-sicps/) were followed to prevent cross-contamination and spread of Covid-19. 78 2.2. Clinical data 79 A descriptive retrospective investigation of the occurrence of MDR bacteria in patients 80 treated at the hospital from January 2021 to April 2023, patients' samples were collected from 81 the different hospital departments as a part of routine testing or when infections were 82 suspected /presumed to be the cause underlying diseases (ICU, NICU, OPD, male ward, 83 female ward, paediatric ward, and medicine ward). Clinical data information relevant to this study was collected and extracted from the departments mentioned above, patient medical 85 charts, infection control surveillance forms, and microbiology laboratory results. The clinical data extracted also included - patient symptoms and comorbidities, neoplasm-related data and 87 its treatment, and most importantly, MDR related infectious microorganisms and their resistance pattern (based on sensitivity to antibiotics, which are recorded data from microbiology laboratory culture test blood culture, etc.) MDRs were determined by applying 90 the Centres for Disease Control and Prevention (CDC) parameters (Horan et al., 2008). 2.3. Bacterial identification and susceptibility testing 92 Microbial isolates were determined by applying the BD Phoenix Automated Microbiology 93 System (USA) and Kirby-Bauer disk diffusion technique (Clinical and Laboratory Standards Institute, 2006.). The protocol detailed, by Caroll et al. (2006) and Hudzicki (2009), were applied to identification and antimicrobial susceptibility tests. Microorganism cultures were

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

obtained from patient samples from different anatomical locations on the body. We examined body fluids such as pus, urine, swabs (from the foot and near the colon), sputum, stool, BAL (Bronchoalveolar lavage) fluid, and ET (Endotracheal Secretion) secretion to determine the occurrence of antibiotic-resistant microbes or pathogens across the samples. The isolates Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter sp., and Citrobacter sp., were examined to be MDR. An infection at many sites in the same patient was revealed as distinct infection events, except that an identical microbe was revealed concurrently. The clinical outcomes were evaluated up to hospital discharge or patient death. For the reasons of this study, patient death was determined concerning the HAIs/ or as non-HAIs-associated in agreement with the professional (Medical) who endorsed the patient death, including clinical chart data examined by three of the authors of this study. 2.4. Statistical analysis Descriptive statistics were used for categorised variables and expressed in terms of per cent frequency. The normal distribution and diversity (alpha and beta) index were applied to determine the variations in MDR-microbial populations between MDR patient samples (collected from 2021, 2022, and 2023 at SUHRC, Pune) used in this study. 3. Results 3.1. Overview of patient infection across all the samples One hundred patients aged one day to 98 years were included (data not shown). Eighty-five patients (out of 100 patients) were treated successfully and discharged (Table 1, data not shown), five patients (out of 100 patients) died (Table 1) in the hospital, and there was no clarity in the reporting of 10 patients' data whether they discharged or died. Fifty-three patients (53 %), 38 patients (38 %), and nine patients (9 %) were male, female, and child (female), respectively (Table 1, Fig. S1) with various clinical characteristics (data not shown

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

and Table 1). An overall lowest death rate of males were observed among patients (Fig. 1A). Patients with comorbidities or with no comorbidities are shown in Table 1. 18 patients with no co-existing comorbidities were observed (Table 1 and data not shown). The medical conditions at presentation or during the hospital study included; UTI (urinary tract infection, 35 % patient), sepsis (16 % patient), foot gangrene (3 % patient), respiratory disease (2 % patient), cancer (1 % patient), hepatic disease (1 % patient), hepatic cyst (1 % patient), asthma (1 % patient), IHD (ischemic heart disease, 1 % patient), CKD (chronic kidney disease, 1 % patient), septic shock (1 % patient), post-CAR (chimeric antigen receptors, 1 % patient) T-cell therapy, hyperthyroidism (1 % patient), osteoporosis (1 % patient), hemoperitoneum (1 % patient), multiple vessel (1 % patient), HIE (hypoxic-ischemic encephalopathy, 1 % patient), femur fracture (1 % patient), that were simultaneously present in a patient (Table 1). Table 2 revealed the sample type distribution and predominance of MDR-gram-negative bacteria (MGNB). The sample urine from the patient showed the highest number (61) of MGNB (Table 2). In comparison the lowest number (2) of MGNB was present in stool samples (**Table 2**). In terms of bacterial species identified in the samples, MDR-Klebsiella pneumoniae was predominant in urine samples (**Table 2**). 3.2. Evaluation of antibiotic resistance To evaluate antibiotic resistance, an antimicrobial susceptibility test (AST) was performed (**Table S1**). The AST of five GNBs, *Klebsiella pneumoniae* (*K. pneumoniae*), followed by Escherichia coli (E. coli), Citrobacter sp., Pseudomonas aeruginosa (P. aeruginosa), and Acinetobacter sp., were determined during our investigation (Table S1). Thirty-one antibiotics were used for susceptibility tests to reveal the MDR characteristics of GNBs isolated from patients. All five GNBs (K. pneumoniae, E. coli, Citrobacter sp., P. aeruginosa, and Acinetobacter sp.) showed the highest (100 %) resistance to ampicillin, ceftazidime, and ertapenem (Table S1). K. pneumoniae, E. coli, P. aeruginosa, and Acinetobacter sp. were

146

147

148

149

151

152

153

154

155

156

157

158

159

161

162

163

164

165

166

167

168

ampicillin/sulbactum-resistant (100 %) (**Table S1**). K. pneumoniae, E. coli, Citrobacter sp., and P. aeruginosa were aztreonam-resistant (100 %) (Table S1). K. pneumoniae, E. coli, Citrobacter sp., and Acinetobacter sp. were ceftriaxone- and cefuroxime-resistant (100 %) (Table S1). K. pneumoniae, Citrobacter sp., and Acinetobacter sp. were cefotaxime- and cefixime-resistant (100 %) (**Table S1**). Citrobacter sp., P. aeruginosa, and Acinetobacter sp. 150 were cotrimoxazole-, meropenem-, and gentamicin-resistant (100 %) (Table S1). E. coli, P. aeruginosa, and Acinetobacter sp. were ciprofloxacin-resistant (100 %) (Table S1). Citrobacter sp. and Acinetobacter sp. were amikacin-, cefepime-, and tobramycin-resistant (100 %) (**Table S1**). E. coli and Citrobacter sp. were ceftazidime avibactam-resistant (100 %) (Table S1). K. pneumoniae and E. coli were cefazolin-, norfloxacin-resistant (100 %) (Table S1). K. pneumoniae and Acinetobacter sp. were imipenem-, nitrofurantoin-, and piperacillin tazobactam-resistant (100 %) (Table S1). Acinetobacter sp. was amoxicillin clavulanic acid-, ceftazidime clavulanic acid-, cefoxitin-, and minocycline-resistant (100 %) (Table S1). E. coli was doripenem-resistant (100 %) (Table S1). Further, E. coli was tigecycline- and tetracycline-susceptible (100 %) (**Table S1**). 160 3.3. Identification of MGNB across all the samples A total of 100 MGNBs belonging to c_Gammaproteobacteria, were identified across all the samples. 28 %, 56 %, and 16 % MGNB were observed in 2021, 2022, and the early part of 2023, respectively (**Fig. 1B**). Further, in the year 2021, 14 adult males, 11 adult females, and 3 children (female) were infected with MGNB, while in the year 2022, 29 adult males, 23 adult females, and 4 children (female) were found to be diseased with MGNB (Fig. 1C). Furthermore, in 2023, 10 adult males, 4 adult females, and 2 children (female) were infected with MGNB (Fig. 1C). The highest number of adult males, adult female, and children (female) patients with MGNB was revealed in the year 2022 (Fig. 1C), while the lowest

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

number of adult male, adult female, and children (female) patients with MGNB were observed in the year 2023 (**Fig. 1C**). In 100 MGNB isolates, Pseudomonadota was noticed as the dominant phylum among the patient samples. Pseudomonadota alone shared 28, 56, and 16 of the total MGNB isolates in the patient samples collected in 2021, 2022, and 2023, respectively (Fig. 1B). The dominant MGNB isolates belonging to Gammaproteobacteria among the patient samples (**Fig. 1D**) depiced the genera E. coli (28 % isolates), Citrobacter sp. (19 % isolates), K. pneumoniae (40 % isolates), P. aeruginosa (7 % isolates), and Acinetobacter sp. (7 % isolates) (**Fig. S2**). 3.4. Specific and shared MGNB population The number of distinct and shared MGNB isolates present in the patient samples were examined applying Venn diagram (http://bioinformatics.psb.ugent.be/cgibin/liste/Venn/calculate venn.htpl) (Fig. 1E, Table S2). Five shared MGNB populations were identified across all samples. E. coli, K. pneumoniae, and Citrobacter sp. were shared between three patient samples (2021, 2022, and 2023), while P. aeruginosa and Acinetobacter sp. were shared between only two patient (2021 and 2022) and (2022 and 2023) samples, respectively (**Fig. 1E, Table S2**). 3.5. Identification of MGNB in patient (with comorbid) samples K. pneumoniae, E. coli, and Citrobacter sp. were present in the patient (with comorbid medical conditions) samples collected in 2021 (Fig. S3A). E. coli (in UTI) was highest among the patient (with comorbid) samples (Fig. S3A), while E. coli (in sepsis and hepatic cyst), K. pneumoniae (in foot gangrene, respiratory disease, and Asthma), Citrobacter sp. (in femur fracture) were noted lowest in the patient (with comorbid) samples (Fig. S3A).

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

K. pneumoniae, E. coli, P. aeruginosa, Citrobacter sp., and Acinetobacter sp. were identified in patient (with comorbid medical conditions) samples collected in 2022 (Fig. **S3B**). K. pneumoniae (in UTI) was highest among the patient (with comorbid) samples (Fig. **S3B**) while E. coli (in sepsis, septic shock, cancer, and hemoperitonen), Citrobacter sp. (in sepsis, post-CAR, and osteoporosis), K. pneumoniae (in foot gangrene, respiratory disease, IHD, CKD, hepatic disease, hyperthyroidism) and P. aeruginosa (in foot gangrene) had the lowest representation in patient (with comorbid) samples (Fig. S3B). K. pneumoniae, E. coli, Citrobacter sp., and Acinetobacter sp. were observed in the patient (with comorbid medical conditions) samples collected in 2023 (Fig. S3C). E. coli (in UTI) was highest among the patient (with comorbid) samples (Fig. S3C), while K. pneumoniae (in sepsis and multiple vessels), Acinetobacter sp. (in UTI and in HIE) had the lowest representation in the patient (with comorbid) samples (Fig. S3C). 3.6. Variance indices Normal distribution, alpha and beta-diversity (taxonomic variance) of the MGNB population was determined utilizing data from various patient' samples. The Shapiro-Wilk (S-W) and Anderson-Darling (A-D) normality test were used to determine distributions of MGNB community within the patient samples. (Table S3). The S-W analysis for normality varied from 0.800 to 0.888, with a *P-value* of 0.081 to 0.351. The observed A-D normal distribution differed from 0.343 to 0.511, with a *P-value* of 0.098 to 0.315 (**Table S3**). The Alpha (α)diversity metrics (Shannon, Simpson, Evenness, Brillouin, Fisher alpha, Chao1, and ACE) of the MGNB population were differed notably within the patient samples (Table 3). The values of Shannon diversity (1.138 to 1.508), Simpson diversity (0.643 to 0.775), Evenness diversity (0.780 to 1.042), and Brillouin diversity (0.933 to 1.340) (**Table 3**) revealed community structure with moderate species richness and abundance in patient samples. The values of

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

Fisher alpha and Chao1 ranged from 1.277 to 1.712 and 4 to 5, respectively (**Table 3**). The ACE (abundance-based coverage estimator; a species richness index) varied from 4.000 to 5.111, with the increase index in MDR bacteria in 2021 among the patient samples (**Table 3**). Notably, the MDRs in the sample (2022) had more MGNB population than the other samples (**Table 3**). Palaeontological Statistics (PAST, v3) software package was applied to determine the beta (β) diversity of the MGNB population between the patient samples (Fig. 2A) collected in 2021, 2022, and 2023. PCoA (principal coordinate analysis, based on the Bray-Kurtis index) was computed using eigenvalues and eigenvectors (coordinates) algorithm from Davis (1986). Before Eigen investigation, PCoA eigen values were produced to the transformation exponent (the power of C), and the definitive index was C = 2. The "Eigen value scaling" measure was applied for each axis, applying the square root of the eigen matrix (value), and the minimum spanning tree preference was based on the picked PCoA matrix. PCoA revealed the existence or absence of MGNB elements between the patient (2021, 2022, and 2023) samples (Fig. 2A). Further, analysis of the data, of pair-wise patient sample, comparisons was determined by applying the Bray-Kurtis similarity and dissimilarity index (Table S4). Bray-Kurtis pairwise similarity and distance index of the patient samples varied from 0.444 - 1.000 (Table S4). Moreover, the Whittaker indexes for the resemblance between MGNB population of the patient samples ranged from 0.11 - 0.25 (**Table S5**). 3.7. Comparison of MGNB populations between de Souza GHA et al. (2023), Ruegsegger et al. (2022), and in the present study In an effort to understand and correlate the MGNB populations of the present study bacterial communities with that present in the study of de Souza GHA et al. (2023), and Ruegsegger et al. (2022) (Fig. 2B, Table 4). Pseudomonas sp. and Klebsiell sp. were revealed at 6.0 and 40.0 %, respectively, in the present study, while in the de Souza GHA et al. (2023), they were noted at 11.4 and 40.0 % (Fig. 2B, Table 4). Further, E. coli and Citrobacter sp. were

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

observed at 28.0 and 19.0 %, respectively in the present study, while in the de Souza GHA et al. (2023) they were noted at 2.8 and 2.8 % (Fig. 2B, Table 4). Furthermore, Acinetobacter sp. was present at 7.0 % in the present study, while in the de Souza GHA et al. (2023) they were revealed at 20.0 % (Fig. 2B, Table 4). Pseudomonas sp. and Klebsiella sp. were present at 6.0 and 40.0 %, respectively, in the present study, while Ruegsegger et al. (2023), reported 34.0 and 14.0 %, respectively (Fig. **2B**, Table 4). Further, E. coli and Citrobacter sp. were present at 28.0 and 19.0 %, respectively, in the present study, while Ruegsegger et al. (2023) reported 7.0 and 7.0 %, respectively (Fig. 2B, Table 4). Furthermore, Acinetobacter sp. was present at 7.0 %, in the present study, while in the Ruegsegger et al. (2023) study, they were not reported (Fig. 2B, Table 4). 4. Discussion GNB are an important public health issue globally due to their antibiotic resistance characteristic (Oliveira and Reygaert, 2022). The invasion of the host by bacteria and the resulting infection is a versatile mechanism that includes various biological factors, i.e. the host defense mechanism, the prevalence and antibiotic susceptibility pattern of microbial isolates, various bio-physicochemical and genetic attributes (Peterson, 1996). The various virulence factors (persistence, transmissibility (ratio of output to input), cling to host cells, host cells invasion, toxigenicity, and the capability to elude or live the host's defence mechanism) of bacteria have been extensively investigated and have shown to have a negative impact on patient's health, particularly when a patient is immunocompromised due

to severe disease (Freeman et al., 2020; Moradi et al., 2021). Moreover, it would be valuable

to investigate whether patient genotypes can influence survival by influencing the number of

MGNB within them (increased or decreased count of MGNB).

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

ICU-MDR percentages are maximum than in other hospital wards (Table 1) due to the multiple associations between the patient's underlying medical conditions, hospital ward type, LOS (length of stay), and employment of various invasive tools (Erbay et al., 2003; Inweregbu et al., 2005; Vincent et al., 2009). Among the 100 patients investigated, 85 (85 %) were discharged, while 5 (5 %) expired in the hospital (Fig. 1A). An overall lower mortality rate was found among elderly, severe patients (with comorbidities) admitted to the different units of the hospital. Our outcomes are not in concurrence with the investigations of Juliana et al. (2022) and Boorgula et al. (2022), who revealed a higher death rate in serious patients. Taking this observation into consideration, we speculate that the lower mortality rate, in our study, might be due to the higher immunity of studied patients during their hospitalization (Parohan et al., 2020; Weiss and Murdoch, 2020; Ejaz et al., 2020). However, such intrinsic protective factors have yet to be determined in specific populations to make the above claims regarding mortality. In our investigation, K. pneumoniae, E. coli, Citrobacter sp., Acinetobacter sp., P. aeruginosa were the most frequent isolates (GNB) in various patient' samples (Vijay et al., 2021; Sharifipour et al., 2020). GNB isolates were higher in adult males than in adult females and children (female) (Fig. 1C). With this observation in view, we hypothesize that a higher level of an enzyme called carboxypeptidase (ACE 2, angiotensin-converting enzyme 2) in men and the predisposition of adult females (at reproductive age) to autoimmune disorder than infectious diseases might be the two reasons for higher MDR-GNB male than in female. Lifestyles of men (heavy smoking and drinking) make them more susceptible to infections (Ramírez-Soto et al., 2021; Bwire, 2020). Nevertheless, this is yet to be elucidated. Regarding AST, we revealed *Acinetobacter* sp. to be the most (100 %) resistant strain when measured against twenty antibiotics (**Table S1**), while *Klebsiella* sp., was found to be 100 %

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

resistant against eleven antibiotics (Table S1). All these five different bacterial species (Table S1) were resistant to numerous antimicrobial agents, which gives them the title of multidrugresistant bacteria (Giannitsioti et al., 2022). Surprisingly antibacterial resistance, in this study, is related to a decrease in the mortality rate compared with the previous study (Tanwar et al., 2014). Our data provides evidence of an increase in antimicrobial resistance post-Covid-19 (Fig. 1C, data collected in 2022). This is in keeping with previous reports that have mentioned a similar pattern of increased antimicrobial resistance in specific locations (Shomuyiwa et al., 2022). Indiscriminate and irrational antimicrobial use and weak antimicrobials regulatory ecosystem, which could be partially attributed to health systems disruption by inadequate access to health services during the Covid-19 pandemic, are suggested causes for the rapid growth of antimicrobial resistance in the community (Lobie et al., 2021; Shomuyiwa et al., 2022). Given the rapid increase in antimicrobial resistance post-Covid-19 in our study, it is important to further analyze how the policies adopted to manage Covid-19 (i.e. widespread antibiotic and disinfectant usage) affect or have a long-lasting consequence on antimicrobial resistance (AMR) (Nieuwlaat et al., 2021). Furthermore, programs at a governmental level need to be adopted widely, particularly in low- and middle-income countries (LMIC), to contain the possible increase in AMR (Lucien et al., 2021). 5. Conclusion In conclusion, outcomes achieved from the present investigation revealed that MDRmicrobes present in patients are predominantly elements of the gamma-proteobacteria. Antibacterial resistance has an important impact on therapeutics and the outcome of bacterial infection. In this study, five gram-negative bacteria, K. pneumoniae, E. coli, Citrobacter sp., Acinetobacter sp., and P. aeruginosa, had increased resistance to the antibacterial agents

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

applied. Therefore, it is essential that the public health and drug susceptibility patterns of microorganisms initiating pathogen infection are continually observed to instruct clinical trials and treatment strategies, thereby reducing the appearance of multi-drug-resistant microbial pathogens. **Declarations** Ethics approval and consent to participate Patient samples and data were collected from the Symbiosis University Hospital and Research Centre (SUHRC), the Symbiosis International University, Pune, Maharashtra, India. **Consent to publish** Not applicable. Availability of data and materials All data is given in the main body of the manuscript; materials are available from the authors. All sequence data is added to manuscript as supplementary files (named as Figure S1 to S3, and Tables S1 to S6). **Competing interests** The authors declare that they have no competing interests. **Funding** No funds were used for this study. **Authors' contributions** A.O. made substantial contributions to conception, was involved in analysis & interpretation of data, writing, revising and drafting the manuscript, and given final approval of the version to be published. D.W. made substantial contributions to writing discussion, editing the

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

manuscript, was involved in revising the manuscript, and given final approval of the version to be published. S.K. made substantial contributions to collect the data from SUHRC and given final approval of the version to be published. All authors reviewed the manuscript and given final approval of the version to be published. **Authors' Information** Symbiosis Institute of Health Sciences, Symbiosis International (Deemed University), Lavale (Hill Base), Pune 412115, Maharashtra, India. Acknowledgments We thank director, Symbiosis Institute of Health Sciences (SIHS) and Head, Symbiosis University Hospital and Research Centre (SUHRC), Pune for kind support. References 1. Alós, J.I., 2015. Resistencia bacteriana a los antibióticos: una crisis global [Antibiotic resistance: A global crisis]. Enferm Infect Microbiol Clin. 33(10), 692-699. https://doi.org/10.1016/j.eimc.2014.10.004. PMID 25475657. 2. Hernando-Amado, S., Coque, T.M., Baquero, F., Martínez, J.L., 2019. Defining and combating antibiotic resistance from one health and global health perspectives. Nat Microbiol. 4(9), 1432-1442. https://doi.org/10.1038/s41564-019-0503-9. 3. Klein, E.Y., Van Boeckel, T.P., Martinez, E.M., Pant, S., Gandra, S., Levin, S.A., Goossens, H., Laxminarayan, R., 2018. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci USA. 115(15), E3463-E3470. https://doi.org/10.1073/pnas.1717295115.

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

4. Carvalho, M.J., Sands, K., Thomson, K., Portal, E., Mathias, J., Milton, R., Gillespie, D., Dyer, C., Akpulu, C., Boostrom, I., Hogan, P., Saif, H., Ferreira, A., Nieto, M., Hender, T., Hood, K., Andrews, R., Watkins, W.J., Hassan, B., Chan, G., Bekele, D., Solomon, S., Metaferia, G., Basu, S., Naha, S., Sinha, A., Chakravorty, P., Mukherjee, S., Iregbu, K., Modibbo, F., Uwaezuoke, S., Audu, L., Edwin, C.P., Yusuf, A.H., Adeleye, A., Mukkadas, A.S., Zahra, R., Shirazi, H., Muhammad, A., Ullah, S.N., Jan, M.H., Akif, S., Mazarati, J.B., Rucogoza, A., Gaju, L., Mehtar, S., Bulabula, A.N.H., Whitelaw, A., Roberts, L., BARNARDS, Group., Walsh, T.R., 2022. Antibiotic resistance genes in the gut microbiota of mothers and linked neonates with or without sepsis from low- and middle-income countries. Nat Microbiol. 7(9), 1337-1347. https://doi.org/10.1038/s41564-022-01184-y. 5. Jones, R.N., 2001. Resistance patterns among nosocomial pathogens: trends over past few years. Chest. 119(2 Suppl), 397S-404S. https://doi.org/ 10.1378/chest.119.2_suppl.397s. 6. Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E., Gilbert, D., Rice, L.B., Scheld, M., Spellberg, B., Bartlett, J., 2009. Bad bugs, no drugs: no ESKAPE! an update from the infectious diseases society of America. Clin Infect Dis. 48(1), 1-12. https://doi.org/10.1086/595011. 7. Aly, N.Y., Al-Mousa, H.H., Al Asarel, S.M., 2008. Nosocomial infections in a medical-surgical intensive care unit. Med Princ Pract. 17(5), 373-377. https://doi.org/10.1159/000141500. 8. Memish, Z.A., and El-Saed, A., 2009. Nosocomial infections in a medical-surgical intensive care unit in Kuwait. Med Princ Pract. 18(4), 342; author reply 342-343. https://doi.org/10.1159/000215737.

- 9. Nannini, M., Foddi, F., Murgia, G., Pisci, R., Sanna, F., Testa, M., Accotto, G.P.,
- 383 2009. An epidemiological survey of TYLCD in southern Sardinia (Italy).
- 384 Commun Agric Appl Biol Sci. 74(3), 831-841. PMID 20222569.
- 385 10. Jindal, A.K., Pandya, K., Khan, I.D., 2015. Antimicrobial resistance: a public
- health challenge. Med J Armed Forces India. 71(2), 178-181.
- 387 https://doi.org/10.1016/j.mjafi.2014.04.011.
- 11. Dogru, A., Sargin, F., Celik, M., Sagiroglu, A.E., Goksel, M.M., Sayhan, H., 2010.
- The rate of device-associated nosocomial infections in a medical surgical
- intensive care unit of a training and research hospital in Turkey: one-year
- 391 outcomes. Jpn J Infect Dis. 63(2), 95-98. PMID 20332569.
- 392 12. Teng, S.O., Lee, W.S., Ou, T.Y., Hsieh, Y.C., Lee, W.C., Lin, Y.C., 2009. Bacterial
- 393 contamination of patients' medical charts in a surgical ward and the intensive care
- unit: impact on nosocomial infections. J Microbiol Immunol Infect. 42(1), 86-91.
- 395 PMID 19424563.
- 13. Dettenkofer, M., Ebner, W., Els, T., Babikir, R., Lucking, C., Pelz, K., Rüden, H.,
- Daschner, F., 2001. Surveillance of nosocomial infections in a neurology intensive
- care unit. J Neurol. 248(11), 959-964. https://doi.org/10.1007/s004150170048.
- 14. Ylipalosaari, P., Ala-Kokko, T.I., Laurila, J., Ohtonen, P., Syrjälä, H., 2006.
- 400 Intensive care acquired infection is an independent risk factor for hospital
- 401 mortality: a prospective cohort study. Crit Care. 10(2), R66.
- 402 https://doi.org/10.1186/cc4902.
- 403 15. Weinstein, R.A., 1998. Nosocomial infection update. Emerg Infect Dis. 4(3), 416-
- 404 420. https://doi.org/10.3201/eid0403.980320.
- 405 16. Iskandar, K., Roques, C., Hallit, S., Husni-Samaha, R., Dirani, N., Rizk, R., Abdo,
- 406 R., Yared, Y., Matta, M., Mostafa, I., Matta, R., Salameh, P., Molinier, L., 2021.

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

The healthcare costs of antimicrobial resistance in Lebanon: a multi-centre prospective cohort study from the payer perspective. BMC Infect Dis. 21(1), 404. https://doi.org/10.1186/s12879-021-06084-w. 17. Neidell, M.J., Cohen, B., Furuya, Y., Hill, J., Jeon, C.Y., Glied, S., Larson, E.L., 2012. Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis. 55(6), 807-815. https://doi.org/10.1093/cid/cis552. 18. Montassier, E., Batard, E., Gastinne, T., Potel, G., de La Cochetière, M.F., 2013. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. Eur J Clin Microbiol Infect Dis. 32(7), 841-850. https://doi.org/10.1007/s10096-013-1819-7. 19. Gastmeier, P., Sohr, D., Geffers, C., Behnke, M., Daschner, F., Rüden, H., 2005. Mortality risk factors with nosocomial Staphylococcus aureus infections in intensive care units: results from the German nosocomial infection surveillance system (KISS). Infection. 33(2), 50-55. https://doi.org/10.1007/s15010-005-3186-5. 20. Horan, T.C., Andrus, M., Dudeck, M.A., 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 36(5), 309-332. https://doi.org/10.1016/j.ajic.2008.03.002. Erratum in: Am J Infect Control. 36(9), 655. PMID 18538699. 21. Clinical and Laboratory Standards Institute, 2006. Performance standards for antimicrobial susceptibility testing. 13th Informational Supplement, Vol. 25, No. 26. Approved Standard M2-A7. Wayne, PA: CLSI.

431 22. Carroll, K.C., Glanz, B.D., Borek, A.P., Burger, C., Bhally, H.S., Henciak, S., 432 Flayhart, D., 2006. Evaluation of the BD phoenix automated microbiology system 433 for identification and antimicrobial susceptibility testing of Enterobacteriaceae. J 434 Clin Microbiol. 44(10), 3506-3509. https://doi.org/10.1128/JCM.00994-06. 23. Hudzicki, J., 2009. Kirby-Bauer disk diffusion susceptibility test protocol. 435 436 American Society for Microbiology. 437 24. Davis, J.C., 1986. Statistics and Data Analysis in Geology. John Wiley & Sons. 438 25. de Souza, G.H.A., de Oliveira, A.R., Dos Santos Barbosa, M., Rossato, L., da Silva Barbosa, K., Simionatto, S., 2023. Multidrug-resistant gram-negative 439 440 bacteria in patients with COVID-19: an epidemiological and clinical study. J 441 Infect Public Health. 16(8), 1184-1192. https://doi.org/10.1016/j.jiph.2023.05.017. 442 26. Ruegsegger, L., Xiao, J., Naziripour, A., Kanumuambidi, T., Brown, D., Williams, 443 F., Marshall, S.H., Rudin, S.D., Yen, K., Chu, T., Chen, L., Sozzi, E., Bartelt, L., 444 Kreiswirth, B., Bonomo, R.A., van Duin, D., 2022. Multidrug-resistant gram-445 negative bacteria in burn patients. Antimicrob Agents Chemother. 66(9), 446 e0068822. https://doi.org/10.1128/aac.00688-22. 27. Oliveira, J., Reygaert, W.C., 2022. Gram-negative bacteria. In: StatPearls 447 448 [Internet]. Treasure Island (FL): StatPearls Publishing. PMID 30855801. 449 28. Peterson, J.W., 1996. Bacterial pathogenesis. In: Baron S, editor. Medical 450 Microbiology. 4th ed. Galveston (TX): University of Texas Medical Branch at 451 Galveston. Chapter 7. PMID 21413346. 29. Freeman, A.M., Leigh, T.R., 2020. JrViral Pneumonia. In: StatPearls. StatPearls 452 453 Publishing. Treasure Island (FL) PMID 30020658. 454 30. Moradi, N., Kazemi, N., Ghaemi, M., Mirzaei, B., 2021. Frequency and

antimicrobial resistance pattern of bacterial isolates from patients with COVID-19

455

456 in two hospitals of Zanjan. Iran Microbiol. 13(6), 769-778. 457 https://doi.org/10.18502/ijm.v13i6.8078. 31. Erbay, H., Yalcin, A.N., Serin, S., Turgut, H., Tomatir, E., Cetin, B., Zencir, M., 458 459 2003. Nosocomial infections in intensive care unit in a Turkish university hospital: 460 Med. 29(9), 1482-1488. 2-year survey. Intensive Care 461 https://doi.org/10.1007/s00134-003-1788-x. 32. Inweregbu, K., and others., 2005. Nosocomial infections, continuing education in 462 critical 463 anaesthesia care & pain. 5(1), 14-17, https://doi.org/10.1093/bjaceaccp/mki006. 464 465 33. Vincent, J.L., Rello, J., Marshall, J., Silva, E., Anzueto, A., Martin, C.D., Moreno, 466 R., Lipman, J., Gomersall, C., Sakr, Y., Reinhart, K., 2009. EPIC II group of 467 investigators. International study of the prevalence and outcomes of infection in 468 intensive care units. JAMA. 302(21), 2323-2329. https://doi.org/10.1001/jama.2009.1754. 469 34. Juliana, A., Ramya, S., Leela, K.V., 2022. Prevalence and antimicrobial 470 susceptibility pattern of secondary gram-negative bacteria isolated from severe 471 acute respiratory syndrome coronavirus disease 2 patients in a tertiary care 472 473 hospital. J Pure Appl Microbiol. 16(4),2514-2520. 474 https://doi.org/10.22207/JPAM.16.4.13. 35. Boorgula, S.Y., Yelamanchili, S., Kottapalli, P., Naga, M.D., 2022. An update on 475 476 secondary bacterial and fungal infections and their antimicrobial resistance pattern (AMR) in Covid-19 confirmed patients. J Lab Physicians. 14(3), 260-264. 477 https://doi.org/10.1055/s-0041-1741438. 478 479 36. Parohan, M., Yaghoubi, S., Seraji, A., Javanbakht, M.H., Sarraf, P., Djalali, M., 480 2020. Risk factors for mortality in patients with coronavirus disease 2019 (Covid481 19) infection: a systematic review and meta-analysis of observational studies. 482 Aging Male. 23(5),1416-1424. https://doi.org/10.1080/13685538.2020.1774748. 483 37. Weiss, P., Murdoch, D.R., 2020. Clinical course and mortality risk of severe 484 Covid-19. Lancet. 395(10229), 1014-1015. https://doi.org/10.1016/S0140-485 6736(20)30633-4. 486 38. Ejaz, H., Alsrhani, A., Zafar, A., Javed, H., Junaid, K., Abdalla, A.E., Abosalif, K.O.A., Ahmed, Z., Younas, S., 2020. Covid-19 and comorbidities: deleterious 487 488 impact on infected patients. J Infect Public Health. 13(12), 1833-1839. https://doi.org/10.1016/j.jiph.2020.07.014. 489 490 39. Vijay, S., Bansal, N., Rao, B.K., Veeraraghavan, B., Rodrigues, C., Wattal, C., 491 Goyal, J.P., Tadepalli, K., Mathur, P., Venkateswaran, R., Venkatasubramanian, R., 492 Khadanga, S., Bhattacharya, S., Mukherjee, S., Baveja, S., Sistla, S., Panda, S., 493 Walia, K., 2021. Secondary infections in hospitalized Covid-19 patients: Indian 494 experience. Infect Drug Resist. 14, 1893-1903. 495 https://doi.org/10.2147/IDR.S299774. 40. Sharifipour, E., Shams, S., Esmkhani, M., Khodadadi, J., Fotouhi-Ardakani, R., 496 497 Koohpaei, A., Doosti, Z., Ej Golzari, S., 2020. Evaluation of bacterial co-498 infections of the respiratory tract in Covid-19 patients admitted to ICU. BMC 499 Infect Dis. 20(1), 646. https://doi.org/10.1186/s12879-020-05374-z. 500 41. Ramírez-Soto, M.C., Arroyo-Hernández, H., Ortega-Cáceres, G., 2021. Sex 501 differences in the incidence, mortality, and fatality of Covid-19 in Peru. PLoS One. 16(6), e0253193. https://doi.org/10.1371/journal.pone.0253193. 502 503 42. Bwire, G.M., 2020. Coronavirus: Why men are more vulnerable to Covid-19 than 504 women? SN Compr Clin Med. 2(7), 874-876. https://doi.org/10.1007/s42399-020-505 00341-w.

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

43. Giannitsioti, E., Salles, M.J., Mavrogenis, A., Rodriguez-Pardo, D., Los-Arcos, I., Ribera, A., Ariza, J., Del Toro, M.D., Nguyen, S., Senneville, E., Bonnet, E., Chan, M., Pasticci, M.B., Petersdorf, S., Benito, N., O' Connell, N., Blanco García, A., Skaliczki, G., Tattevin, P., Kocak Tufan, Z., Pantazis, N., Megaloikonomos, P.D., Papagelopoulos, P., Soriano, A., Papadopoulos, A., 2022. The Esgiai collaborators Study Group. Osteosynthesis-associated infection of the lower limbs by multidrug-resistant and extensively drug-resistant Gram-negative bacteria: a multicentre cohort study. J Bone Jt Infect. 7(6), 279-288. https://doi.org/10.5194/jbji-7-279-2022. 44. Tanwar, J., Das, S., Fatima, Z., Hameed, S., 2014. Multidrug resistance: an crisis. emerging Interdiscip Perspect Infect Dis. 2014, 541340. https://doi.org/10.1155/2014/541340. 45. Shomuyiwa, D.O., Lucero-Prisno, D.E. 3rd., Manirambona, E., Suleman, M.H., Rayan, R.A., Huang, J., Zaw, T.N., Babatunde, Y., Denkyira, S.A., Musa, S.S., 2022. Curbing antimicrobial resistance in post-Covid Africa: challenges, actions Health Sci 5(5), and recommendations. Rep. e771. https://doi.org/10.1002/hsr2.771. 46. Lobie, T.A., Roba, A.A., Booth, J.A., Kristiansen, K.I., Aseffa, A., Skarstad, K., Bjørås, M., 2021. Antimicrobial resistance: a challenge awaiting the post-Covid-19 era. Int J Infect Dis. 111, 322-325. https://doi.org/10.1016/j.ijid.2021.09.003. 47. Nieuwlaat, R., Mbuagbaw, L., Mertz, D., Burrows, L.L., Bowdish, D.M.E., Moja, L., Wright, G.D., Schünemann, H.J., 2021. Coronavirus disease 2019 and antimicrobial resistance: parallel and interacting health emergencies. Clin Infect Dis. 72(9), 1657-1659. https://doi.org/10.1093/cid/ciaa773.

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

48. Lucien, M.A.B., Canarie, M.F., Kilgore, P.E., Jean-Denis, G., Fénélon, N., Pierre, M., Cerpa, M., Joseph, G.A., Maki, G., Zervos, M.J., Dely, P., Boncy, J., Sati, H., Rio, A.D., Ramon-Pardo, P., 2021. Antibiotics and antimicrobial resistance in the Covid-19 era: Perspective from resource-limited settings. Int J Infect Dis.104, 250-254. https://doi.org/10.1016/j.ijid.2020.12.087. Figure legends Fig. 1 Overview of study. (A) Outcomes of patients with MDR-gram negative bacterial pathogens. (B) Percentage overview of patients with MDR-gram negative bacterial pathogens. (C) Distribution of MDR-gram negative bacterial pathogens in adult male, adult female, and children (female). (D) Relative abundance of different MDR-gram negative bacterial pathogens among all patient samples at the level of genus. (E) Identification of specific and shared MDR-gram negative bacterial pathogens among the patient samples. Fig. 2 Principal coordinate analysis and comparative overview of MGNB communities identified in patients. (A) Analysis of MDR-gram negative bacterial pathogens diversity in the patient samples collected in different, 2021, 2022, and 2023, years. MDR-gram negative bacterial pathogens diversity in the patient samples using principal coordinate analysis (PCoA-Bray-Kurtis index). (B) Comparative overview of MDR-gram negative bacterial communities identified in patient samples of the Hospital-acquired infection (in this study), de Souza GHA et al (2023), and Ruegsegger et al (2022). Table legends **Table 1**| Representation and clinical traits in patients with hospital-acquired infections (HAI, 2021-2023). Table 2| Predominance of MDR-gram negative bacterial pathogens from different sample types of patients.

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572


573

574

Table 3| Alpha-diversity indices and the estimated richness of MDR-gram negative bacterial population in the patient samples. Table 4| Comparative overview of MDR-gram negative bacterial populations identified in patients from investigation of de Souza GHA et al., 2023, Ruegsegger et al., 2022, and in this study. Supplementary material Fig. S11 Overview of MDR-gram negative bacterial pathogens collected from the gender wise patients. Fig. S21 Relative abundance of different MDR-gram negative bacterial pathogens among all patient samples at the level of species. Fig. S31 Description of MDR-gram negative bacterial pathogens among the patient with comorbid condition collected in different, (A) 2021, (B) 2022, and (C) 2023, years from hospital. Table S1 Antimicrobial susceptibility tests. Antimicrobial susceptibility tests of MGNB pathogens collected from patient samples. Table S2| Labeling of specific and shared MGNB communities among the patient samples during Covid-19 and post-Covid-19 year. (A) Specific MGNB communities (specific and shared) in patient samples. (B) Shared MGNB communities in patient samples. **Table S3** Statistics of MGNB collected different years from the patient samples. **Table S4** Bray-Kurtis pairwise similarity and distance (dissimilarity) index of MGNB population among the patient samples collected in 2021, 2022, and 2023.

Table S5| Beta-diversity, Whittaker indexes, and pair-wise comparisons between the patient samples based on MGNB populations.


Fig. 1 A



В


Patient in post-Covid-19 year

16%




C

Patient in Covid-19 year



A



В




Table 11 Characteristics of hospital stay of patients with or without comorbidities, 2021-2023 (Covid-19/ or post Covid-19) period.

S. No.	Characteristic	Patients (N=100)
1	Age (range)	1 day - 98 years
2	Discharged	85 (85 %)
3	Death	5 (5 %)
4	Male (adult)	53 (53 %)
5	Female (adult)	38 (38 %)
6	Children (female)	9 (9 %)
7	Male ward	27 (27 %)
8	Female ward	25 (25 %)
9	Intensive care unit (ICU) admission	29 (29 %)
10	Outpatient department (OPD)	12 (12 %)
11	Pediatric ward	4 (4 %)
12	Neonatal intensive care unit (NICU) admission	1 (1 %)
13	Comorbidities	
a.	no comorbidities	18 (18 %)
b.	Urinary Tract Infection (UTI)	35 (35 %)
c.	Sepsis	16 (16 %)
d.	Foot gangrene	3 (3 %)
e.	Respiratory disease	2 (1 %)
f.	Cancer	1 (1 %)
g.	Hepatic disease	1 (1 %)
h.	Hepatic cyst	1 (1 %)
i.	Asthma	1 (1 %)
j.	Ischemic heart disease (IHD)	1 (1 %)
k.	Chronic kidney disease (CKD)	1 (1 %)
1.	Septic shock	1 (1 %)
m.	Post-compensatory anti-inflammatory response (CAR)	1 (1 %)
n.	Hyperthyroidism	1 (1 %)
0.	Osteoporosis	1 (1 %)
p.	Hemoperitoneum	1 (1 %)
q.	Multiple vessel	1 (1 %)
r.	Hypoxic-ischemic encephalopathy (HIE)	1 (1 %)
S.	Femur fracture	1 (1 %)

medRxiv preprint doi: https://doi.org/10.1101/2024.10.25.24315976; this version posted October 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Table 21 Dominancy of MDR bacterial isolates from different types of patient's sample.

Isolates	Sample types						
	Pus	Urine	SWAB	Sputum	Stool	BAL	ET
Klebsiella pneumoniae	7	20	3	2	2	2	3
Escherichia coli	2	18	4	1	0	0	1
Citrobacter	2	16	0	0	0	0	1
Pseudomonas aeruginosa	1	6	0	0	0	0	0
Acinetobacter	2	1	2	1	0	1	0
Total	14	61	9	4	2	3	4

Note# Pus; A thick, whitish-yellow fluid of WBCs (white blood cells), cellular debris, and liquefied tissue. SWAB; a medical device used for the collection of biological samples from the patient body. BAL; Bronchoalveolar lavage, ET; Endotracheal secretion.

medRxiv preprint doi: https://doi.org/10.1101/2024.10.25.24315976; this version posted October 30, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Table 31 Alpha-diversity metrics of MDR bacterial population in the patient samples.

Sample name	Shannon	Simpson	Evenness	Brilloium	Fisher-alpha	Chao1	ACE	Observed species
2021 (Covid-19)	1.138	0.643	0.780	0.933	1.277	4	5.111	28
2022 (post Covid-19)	1.508	0.755	0.903	1.340	1.328	5	5.000	56
2023 (post Covid-19)	1.427	0.775	1.042	1.077	1.712	4	4.000	16
Total	4.073	2.173	2.725	3.350	4.317	13	14.111	100

Table 4I Comparative synopsis of MDR bacteria observed in present study patient' samples (during Hospital stay), de Souza GHA et al., 2023, and Ruegsegger et al., 2022. (ND; Not determined).

S. No.	MDR microbes	Present study (%)	de Souza GHA et al., 2023, (%)	Ruegsegger et al., 2022, (%)
1	Pseudomonas	6.0	11.4	34.0
2	Klebsiella	40.0	40.0	14.0
3	Escherichia coli	28.0	2.8	7.0
4	Citrobacter	19.0	2.8	7.0
5	Acinetobacter	7.0	20.0	ND